研究单位：[1]Merck KGaA, Darmstadt, Germany[2]307 Hospital of Chinese PLA[3]Beijing Cancer Hospital[4]Tongji Hospital of Tongji Medical Colleague of Huazhong University of Science and Technology
The purpose of this study is to determine whether the cancer vaccine tecemotide (L-BLP25) in addition to best supportive care is effective in prolonging the lives of Asian subjects with unresectable stage III non-small cell lung cancer in comparison to a placebo plus best supportive care (a so-called placebo controlled study).
